MedPage Today April 4, 2024
— We need policies to address high launch prices and anti-competitive patent practices
During his recent State of the Union address, President Biden touted the projected success of the Inflation Reduction Act (IRA) in reducing drug expenditures and called for its expansion to include “500 drugs over the next decade.” However, efforts to weaken the law by House Republicans, and lawsuits from pharmaceutical companies to repeal the IRA, underscore the contentious battle over drug pricing reforms. Despite this opposition, lawsuits in Texas and Delaware challenging IRA Medicare drug price negotiation provisions were dismissed, further solidifying the IRA’s standing for now.
Still, simply expanding the IRA’s scope will unlikely be enough to successfully curb rising drug costs and claim victory over...
Today's Sponsors
Today's Sponsor